Iovance Biotherapeutics reported strong Q4 2025 results with significant revenue growth driven by Amtagvi demand and improved gross margins. The company achieved its full-year revenue guidance and is well-positioned for future profitability with a cash runway extending into Q3 2027.
Fourth quarter 2025 total product revenue of ~$87 million, with strong growth of ~30% over the prior quarter.
positiveFull year 2025 total product revenue of ~$264 million achieved the guidance range of $250 million to $300 million.
positiveFourth quarter 2025 gross margin from cost of sales was ~50%, reflecting increasing benefits from solid execution and cost optimization.
positiveThe cash position as of December 31, 2025 of ~$303 million is expected to fund operations into the third quarter of 2027.
positiveU.S. FDA granted Fast Track Designation for lifileucel in second-line advanced non-small cell lung cancer.
positiveNet Loss for the fourth quarter of 2025 was $71.9 million, or $0.18 per share.
negativeNet Loss for the full year 2025 was $391.0 million, or $1.09 per share.
negativeTotal costs and expenses for the fourth quarter of 2025 were $160.2 million, largely flat compared to the prior year quarter.
attentionLoss from operations for the fourth quarter of 2025 was $73.5 million, an improvement from $86.6 million in the prior year quarter but still a significant loss.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
U.S. Amtagvi | N/A | — | — | — |
Global Proleukin | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Iovance delivered approximately 30 percent quarterly revenue growth and achieved our 2025 guidance range in the first full calendar year of launch. Growth was driven by increasing demand for Amtagvi.
After ongoing improvements in our operations and gross margin, we are well positioned for future profitability.
Iovance is poised to create substantial value for patients and shareholders as we increase revenue while advancing our registrational trial in non-small cell lung cancer and best-in-class TIL pipeline in solid tumors.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.